Literature DB >> 21881215

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.

Simon A Jones1, Jürgen Scheller, Stefan Rose-John.   

Abstract

The successful treatment of certain autoimmune conditions with the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab has emphasized the clinical importance of cytokines that signal through the β-receptor subunit glycoprotein 130 (gp130). In this Review, we explore how gp130 signaling controls disease progression and examine why IL-6 has a special role among these cytokines as an inflammatory regulator. Attention will be given to the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL-6 activity in autoimmunity, inflammation, and cancer.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21881215      PMCID： PMC3163962          DOI： 10.1172/JCI57158

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


  125 in total

1.  Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules.

Authors:  V Modur; M J Feldhaus; A S Weyrich; D L Jicha; S M Prescott; G A Zimmerman; T M McIntyre
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

2.  Actemra poised to launch IL-6 inhibitors.

Authors:  Lisa Melton; Amy Coombs
Journal:  Nat Biotechnol       Date:  2008-09       Impact factor: 54.908

3.  Understanding the IL-23-IL-17 immune pathway.

Authors:  Brent S McKenzie; Robert A Kastelein; Daniel J Cua
Journal:  Trends Immunol       Date:  2005-11-14       Impact factor: 16.687

Review 4.  The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases.

Authors:  Karl-Josef Kallen
Journal:  Biochim Biophys Acta       Date:  2002-11-11

Review 5.  Development of anti-TNF therapy for rheumatoid arthritis.

Authors:  Marc Feldmann
Journal:  Nat Rev Immunol       Date:  2002-05       Impact factor: 53.106

6.  Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.

Authors:  G Lattanzio; C Libert; M Aquilina; M Cappelletti; G Ciliberto; P Musiani; V Poli
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

Review 7.  Predicting the development of RA in patients with early undifferentiated arthritis.

Authors:  Karim Raza; Andrew Filer
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-02       Impact factor: 4.098

8.  STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity.

Authors:  Thomas Welte; Samuel S M Zhang; Tian Wang; Zhiyuan Zhang; David G T Hesslein; Zhinan Yin; Arihiro Kano; Yoshiki Iwamoto; En Li; Joseph E Craft; Alfred L M Bothwell; Erol Fikrig; Pandelakis A Koni; Richard A Flavell; Xin-Yuan Fu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-05       Impact factor: 11.205

9.  Mice lacking the CNTF receptor, unlike mice lacking CNTF, exhibit profound motor neuron deficits at birth.

Authors:  T M DeChiara; R Vejsada; W T Poueymirou; A Acheson; C Suri; J C Conover; B Friedman; J McClain; L Pan; N Stahl; N Y Ip; G D Yancopoulos
Journal:  Cell       Date:  1995-10-20       Impact factor: 41.582

10.  IL-6 regulates neutrophil trafficking during acute inflammation via STAT3.

Authors:  Ceri A Fielding; Rachel M McLoughlin; Louise McLeod; Chantal S Colmont; Meri Najdovska; Dianne Grail; Matthias Ernst; Simon A Jones; Nicholas Topley; Brendan J Jenkins
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422
View more
  261 in total

1.  JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.

Authors:  Andrea Bonetto; Tufan Aydogdu; Xiaoling Jin; Zongxiu Zhang; Rui Zhan; Leopold Puzis; Leonidas G Koniaris; Teresa A Zimmers
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-06-05       Impact factor: 4.310

2.  Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer.

Authors:  Christopher Johnson; Yuyan Han; Nathan Hughart; Jennifer McCarra; Gianfranco Alpini; Fanyin Meng
Journal:  Transl Gastrointest Cancer       Date:  2012-04-01

Review 3.  Emerging cytokine networks in colorectal cancer.

Authors:  Nathan R West; Sarah McCuaig; Fanny Franchini; Fiona Powrie
Journal:  Nat Rev Immunol       Date:  2015-09-11       Impact factor: 53.106

4.  Delayed revascularization of islets after transplantation by IL-6 blockade in pig to non-human primate islet xenotransplantation model.

Authors:  Byoung-Hoon Min; Jun-Seop Shin; Jong-Min Kim; Seong-Jun Kang; Hyun-Je Kim; Il-Hee Yoon; Su-Kyoung Park; Ji-Won Choi; Min-Suk Lee; Chung-Gyu Park
Journal:  Xenotransplantation       Date:  2017-12-06       Impact factor: 3.907

Review 5.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

6.  IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAK-dependent IL-10 expression in macrophages.

Authors:  Poonam Kothari; Roberto Pestana; Rim Mesraoua; Rim Elchaki; K M Faisal Khan; Andrew J Dannenberg; Domenick J Falcone
Journal:  J Immunol       Date:  2013-11-27       Impact factor: 5.422

Review 7.  Interleukin-6: designing specific therapeutics for a complex cytokine.

Authors:  Christoph Garbers; Sylvia Heink; Thomas Korn; Stefan Rose-John
Journal:  Nat Rev Drug Discov       Date:  2018-05-04       Impact factor: 84.694

8.  Therapeutic effect of farnesylthiosalicylic acid on adjuvant-induced arthritis through suppressed release of inflammatory cytokines.

Authors:  E Aizman; E Blacher; O Ben-Moshe; T Kogan; Y Kloog; A Mor
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

9.  Benefits of Multifaceted Chemopreventives in the Suppression of the Oral Squamous Cell Carcinoma (OSCC) Tumorigenic Phenotype.

Authors:  Susan R Mallery; Daren Wang; Brian Santiago; Ping Pei; Steven P Schwendeman; Kari Nieto; Richard Spinney; Meng Tong; George Koutras; Brian Han; Andrew Holpuch; James Lang
Journal:  Cancer Prev Res (Phila)       Date:  2016-10-18

10.  Cellular senescence or EGFR signaling induces Interleukin 6 (IL-6) receptor expression controlled by mammalian target of rapamycin (mTOR).

Authors:  Christoph Garbers; Fabian Kuck; Samadhi Aparicio-Siegmund; Kirstin Konzak; Mareike Kessenbrock; Annika Sommerfeld; Dieter Häussinger; Philipp A Lang; Dirk Brenner; Tak W Mak; Stefan Rose-John; Frank Essmann; Klaus Schulze-Osthoff; Roland P Piekorz; Jürgen Scheller
Journal:  Cell Cycle       Date:  2013-09-18       Impact factor: 4.534
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.